Sensus Healthcare, Inc. is a medical technology company specializing in the design, development and commercialization of superficial radiotherapy systems for the treatment of non-melanoma skin cancers and keloids. Its flagship products, the SRT-100 and SRT-100+ systems, deliver low-energy X-ray therapy in a non-invasive, outpatient setting, providing clinicians with an alternative to surgery and enabling patients to preserve cosmetic appearance and minimize recovery time.
The company’s product portfolio includes the SRT-100 series systems, handpieces and applicators tailored to various lesion sizes and anatomical locations. These systems employ targeted superficial radiation to deliver precise doses to the treatment site while sparing surrounding healthy tissue. Sensus Healthcare also offers comprehensive service, training and maintenance programs designed to support clinic staff and ensure consistent, high-quality patient care.
Founded in the late 1990s and headquartered in Orlando, Florida, Sensus Healthcare has expanded its presence across the United States and into select international markets. The company’s direct sales organization serves dermatology, oncology and plastic surgery practices, while strategic partnerships and distribution agreements facilitate access in Europe, Latin America and the Middle East. Ongoing research and development efforts focus on enhancing device functionality, streamlining clinical workflows and exploring new therapeutic applications.
Under the leadership of Chief Executive Officer José Báez, the company prioritizes regulatory compliance, quality assurance and evidence-based clinical data. Sensus Healthcare’s executive team and board of directors bring extensive experience in medical device innovation, commercial strategy and healthcare operations. Through collaboration with key opinion leaders and professional societies, the company continues to advance the adoption of superficial radiotherapy as a standard of care in dermatologic oncology.
AI Generated. May Contain Errors.
